Nonprofit nursing homes provide better care and more nursing care than investor-owned homes, according to a survey of over 13,500 homes nationwide.
Nonprofit nursing homes provide better care and more nursing care than investor-owned homes, according to a survey of over 13,500 homes nationwide. According to the study, published in The American Journal of Public Health (vol. 91, no. 9), private facilities averaged 5.89 deficiencies per home, 46.5% higher than nonprofit homes and 43% higher than public homes.
In addition, the study found that:
•Â Numbers of licensed nursing hours per patient day at private facilities were 31.7% lower than at nonprofit facilities, and 22% lower than at public homes.
•Â Nursing aide hours at private homes were 11.9% less than at nonprofit facilities and 16% less than at public homes.
•Â Rates of severe deficiencies at investor-owned facilities were 40.5% higher than at nonprofit homes and 35.8% higher than at public homes.
Said the authors, "Our results suggest that investor-owned nursing homes deliver lower-quality care than do nonprofit or public facilities. Moreover, investor-owned facilities usually are part of a chain, and chain ownership per se is associated with a further decrement in quality."
The authors concluded: "The most obvious explanation for our findings is that profit-seeking diverts funds and focus from clinical care." PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.